^
    Back
    Association details:
    Biomarker:ALK fusion
    Cancer:Lung Adenocarcinoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Onco Targets Ther
    Title:

    Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report

    Published date:
    01/25/2023
    Excerpt:
    A 70-year-old woman complained of a cough with blood in her sputum...A stage IVa (cT4N1M1a) lung adenocarcinoma with ALK fusion was diagnosed….One year later, crizotinib was readministered at a half-dose because of disease progression, and the patient achieved stable disease without hepatotoxicity for 9 months.
    DOI:
    10.2147/OTT.S393165
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    J Oncol Pharm Pract
    Title:

    68-months progression-free survival with crizotinib treatment in a patient with metastatic ALK positive lung adenocarcinoma and sarcoidosis: A case report

    Published date:
    08/23/2020
    Excerpt:
    The patient with positive ALK fusion mutation started crizotinib treatment in July 2014. The patient's last response assessment was in March 2020, with 68-progression-free disease with crizotinib....crizotinib in a 68-months progression-free survival in a 62-years old non-smoking female patient with metastatic lung adenocarcinoma...
    DOI:
    10.1177/1078155220951242